Avience Biomedicals (NSE:AVIENCE) ROC (Joel Greenblatt) %: 0.00% (As of Jan. 2026)


NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
5 GF Score
Price ₹414.95
View Full Analysis

What is Avience Biomedicals ROC (Joel Greenblatt) %?

Avience Biomedicals NSE:AVIENCE 5 ROC (Joel Greenblatt) % is 0.00% as of Jan. 2026. GuruFocus rates NSE:AVIENCE with a GF Score™ of 5/100. Among 840 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 119047.5% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Avience Biomedicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was 0.00%.

The historical rank and industry rank for Avience Biomedicals's ROC (Joel Greenblatt) % or its related term are showing as below:

NSE:AVIENCE's ROC (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.035
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Avience Biomedicals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Avience Biomedicals  (NSE:AVIENCE) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Avience Biomedicals ROC (Joel Greenblatt) % Related Terms


Avience Biomedicals ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals ROC (Joel Greenblatt) % Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
ROC (Joel Greenblatt) %
25.82 31.71 38.69

Avience Biomedicals Quarterly Data
Mar23 Mar24 Mar25 Jan26
ROC (Joel Greenblatt) % 0.00 0.00 0.00 0.00

NSE:AVIENCE vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, Avience Biomedicals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avience Biomedicals ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Avience Biomedicals's ROC (Joel Greenblatt) % falls into.


NSE:AVIENCE
5GF Score
Avience Biomedicals Ltd NSE:AVIENCE
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(172.116 + 130.712 + 15.541) - (82.377 + 0 + 29.637)
=206.355

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(195.383 + 158.518 + 14.139) - (80.951 + 0 + 22.763)
=264.326

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Avience Biomedicals for the quarter that ended in Jan. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Jan. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jan. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (176.136 + max(206.355, 0)) + (258.3 + max(264.326, 0)) )/ 2 )
=0/( ( 382.491 + 522.626 )/ 2 )
=0/452.5585
=0.00 %

Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Avience Biomedicals (NSE:AVIENCE) has a ROC (Joel Greenblatt) % of 0.00% as of Jan. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Avience Biomedicals and its competitors. According to the industry distribution chart, Avience Biomedicals ranks #999999 out of 840 companies in the Medical Devices & Instruments industry.
Is Avience Biomedicals' ROC (Joel Greenblatt) % too high?
Avience Biomedicals' current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Avience Biomedicals ranks #999999 out of 840 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avience Biomedicals has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #999999 out of 840 companies for ROC (Joel Greenblatt) %. This places Avience Biomedicals in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current ROC (Joel Greenblatt) % of 0.00%. The current ROC (Joel Greenblatt) % is 0.00%. Avience Biomedicals' overall GF Score™ is 5/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current ROC (Joel Greenblatt) % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
5GF Score

Get the complete analysis for NSE:AVIENCE

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹414.95
Price